相关实验视频
Updated: Jul 18, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.8K
doxorubicin 诱导的心血管毒性:功能和分子标记物的纵向评估
Matthias Bosman1, Dustin Krüger1, Charles Van Assche2
1Laboratory of Physiopharmacology, Faculty of Medicine and Health Sciences, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie Eiken, University of Antwerp, Universiteitsplein 1, Antwerp B-2610, Belgium.
Cardiovascular research
|August 25, 2023
概括
在心脏功能降低之前,多克索鲁比 (DOX) 会导致动脉硬和内皮功能障碍. 新的生物标志物 - - 血栓松丁-1 (THBS1) 和α-1-抗基莫素 (SERPINA3) - - 对检测DOX诱导的心血管毒性显示出希望.
科学领域:
- 心血管科学 心血管科学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗药物多克索鲁比 (DOX) 引起心脏毒性和血管毒性.
- 血管毒性,包括动脉硬和内皮功能障碍,是心血管事件的预测因素.
- 由于DOX引起的血管毒性和可靠的生物标志物的时间概况仍然不清楚.
研究的目的:
- 在小鼠模型中纵向评估DOX诱导心血管毒性的功能和分子标记.
- 在患者血中验证潜在的分子生物标志物.
主要方法:
- 小鼠每周接受DOX或盐水6周.
- 心血管功能,动脉硬性和血管反应性被纵向测量.
- 蛋白质组分析确定了大动脉组织中的分子标记物.
- 生物标志物水平在癌症幸存者的血中得到量化,这些患者有或没有因人环素诱导的心脏毒性 (AICT).
主要成果:
- 在治疗的早期,DOX诱导了动脉硬和受损的内皮依赖血管扩张,先后减少左心室喷射率 (LVEF).
- 血管功能障碍在DOX停止后显示部分恢复,而心脏功能障碍持续存在.
- 在接受DOX治疗的小鼠中,Thrombospondin-1 (THBS1) 和α-1-antichymotrypsin (SERPINA3) 的高调并持续存在.
- 在AICT患者中证实THBS1和SERPINA3水平升高.
结论:
- DOX诱导的血管毒性,包括动脉硬和内皮功能障碍,在心脏毒性之前.
- THBS1和SERPINA3被确定为DOX诱导的心血管毒性的有前途的生物标志物.
- 这些生物标志物在患有AICT的人类患者中得到了验证.
相关概念视频
Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy VI: Nursing Management
13
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
13
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy IV: Restrictive Cardiomyopathy
12
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12

